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Summary 
Background To adequately adjust for confounding multivariable models need to be correctly 
specified and include a sufficient number of subjects per estimated parameter.  
Methods A simulation study was conducted which explored the performance of logistic 
regression (LR), propensity score (PS) analysis and disease risk score (DRS) methods to adjust 
for confounding. Events/exposed subjects per coefficient (EPC) was set to 10, 5, 2.5, 1.0 and 
0.5. Model misspecification was induced by ignoring treatment and/or interaction effects in the 
DRS training data (i.e., independent dataset to develop the DRS model). 
Results At low EPCs of 1.0 and 0.05, the LR estimates had a relative bias of more than 100%. 
Bias of the DRS estimates was at most 13.40% and 18.84%. For the PS model this was 8.80% 
and more than 100%, respectfully. Coverage of the LR estimates became less than the nominal 
level of 0.95 at an EPC of 5 (0.936). For the DRS and PS methods coverage became less than 
0.95 at an ECP of 2.5 and 1.0, respectfully. Depending on the direction of the interaction effect 
relative to the main treatment effect, ignoring the interaction resulted in a bias of 16.94% for the 
DRS models.  
Conclusion In settings with small events/exposed subjects per coefficient, DRS methods can 
be useful alternative to LR models, especially when PS models cannot be used. However, while 
in our simulations DRS estimates were the leased unbiased in low EPCs settings, coverage was 
below acceptable levels after EPC of 2.5 and always less than the more biased PS method.  
Keywords: confounding, statistics, simulations study, logistic regression, propensity score, 
disease risk score. 
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Background 
Nonrandomized studies on (pharmacological) therapeutics are often conducted to complement 
results from randomized clinical trials (RCTs). For example, nonrandomized studies might be 
more appropriate to assess the occurrence of rare, but severe, adverse events such as 
anaphylactic reactions 1-3. Furthermore, nonrandomized studies are used to estimate the 
relative effectiveness in real-life clinical practice. Depending on the relationship between the 
intervention and the outcome, different degrees of confounding can be expected 1-3. For 
example, after launch of a new drug it is expected that patients who responded poorly to older 
drugs cross-over to the new drug (i.e., channelling). In this case the crude association between 
treatment and outcome is very likely confounded4.  
 
Frequently, the outcome of interest is dichotomous, such as mortality, in which case 
multivariable logistic regression (LR) 5 is commonly used to adjust for confounding. One (of 
many) assumption(s), is that the associations between confounders and the outcome are 
sufficiently estimated to adjust for confounding bias. In settings (e.g., nonrandomized early post-
launch studies) where both the number of events and the number of exposed subjects are 
small, controlling for confounding can be problematic. Further complicating the matter is that it is 
not uncommon to consider more than 100 potential confounders 6. Simulation studies showed, 
that for prognostic LR models 10 or more events per coefficient (EPC) were needed to get 
unbiased estimates 7,8. However, in prognostic studies, the interest lies in correctly estimating all 
associations between possible predictors and the outcome, whereas in nonrandomized 
therapeutic studies, the interest is usually in estimating a single association (i.e., the treatment 
outcome association), while adjusting for numerous potential confounders. Vittinghoff and 
McCulloch 9 showed that in this case LR models with EPC as small as 6 can adequately adjust 
for confounding.  
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In settings where LR models are expected to perform poorly (i.e., EPC smaller than 6), 
propensity score (PS) 10,11 and disease risk score (DRS) 12-16 methods can be applied to 
summarize the information of multiple confounders into a single variable. It seems logical that 
these methods require less events/exposures per coefficient. However, it remains unclear how 
many events/exposures per variable are needed to sufficiently control for confounding using PS 
and DRS methods. Furthermore, in training (i.e., developing) DRS models, it is often implicitly 
assumed that there is no treatment effect or no treatment by confounder interaction. How 
sensitive DRS models are to violations of these assumptions is unknown, particularly when the 
DRS model is trained in one dataset and applied in another. We therefore conducted a 
simulation study to compare LR, PS and four kinds of DRS models with varying amount of EPC 
and under different levels of model misspecification.  
 
Methods 
 
Simulation set-up 
Following the examples given above, we focused on scenarios in which the effects of a new 
drug (or any other type of medical intervention) were evaluated early post-launch. In addition, 
pre-launch data on the comparator drug were considered to be available. In each simulation, a 
training dataset was generated, containing pre-launch information, as well as a test dataset, 
containing post-launch information. Each training dataset included 5000 subjects of whom 
approximately 2500 were exposed to the comparator drug C and 2500 to drug B. Approximately 
2500 subjects experienced the event of interest. The test dataset included 400 subjects of 
whom, on average, 200 were exposed to comparator drug C and 200 to the new drug A. 
Approximately 200 subjects in the test data set experienced an event. The training data were 
used to train the DRS models. The test data were then used to compare the estimated effect of 
the intervention (drug A vs. C) obtained through the DRS, LR and PS methods.  
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Data-generating process 
Data of the training and test datasets were generated using the same algorithm. First, 𝑗 
independent confounding variables 𝑍 were generated. 𝑍1 was sampled from a normal 
distribution with mean 3 and variance 1. The remaining 𝑍𝑗−1 variables were sampled from 
independent Bernoulli distributions, each with a success probability of 0.5. A subject’s 
probability of treatment was given by the model:  
 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖,𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) = 𝛼0 +  𝛼1𝑧𝑖1 + ⋯ + 𝛼𝑗𝑧𝑖𝑗       [1] 
 
𝑝𝑖,𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 indicates the probability of the 𝑖𝑡ℎ individual to receive treatment. The value of 𝛼0 
was set so that on average 50% of the subjects were exposed. Please see Table 1 and the 
simulation scenarios section below for an overview parameter values used. For each 
𝑖𝑡ℎ individual the probability of experiencing an event was given by:  
 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖,𝑒𝑣𝑒𝑛𝑡) = 𝛿0 + 𝛿1𝑥𝑖 + 𝛿2𝑧𝑖1 + ⋯ + 𝛿𝑗𝑧𝑖𝑗 + 𝛿𝑖𝑛𝑡𝑥𝑖𝑧𝑖1     [2] 
 
The intercept (𝛿0) was chosen so that on average 50% of the subjects experienced an event. 
Depending on the value of 𝛿𝑖𝑛𝑡 there was an interaction between treatment and continuous 
confounder 𝑍1. The treatment and outcome states were then sampled from Bernoulli 
distributions: 
 
𝑥𝑖~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝𝑖,𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) 
𝑦𝑖~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝𝑖,𝑒𝑣𝑒𝑛𝑡) 
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Data analyses 
The test data contained post launch information on subjects receiving new drug A (indicated 
by 𝑋 = 1) or drug C (indicated by 𝑋 = 0). To adjust for confounding in the association between 
treatment and the outcome the subsequently described methods were applied.  
 
Logistic regression confounding adjustment 
To adjust for confounding the following LR model was used: 
 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑜𝑏[𝑦𝑖 = 1|𝑥𝑖, 𝑧𝑖𝑗]) =  ?̂?0 + ?̂?1𝑥𝑖 + ?̂?1𝑧𝑖1 + ⋯ + ?̂?𝑗𝑧𝑖𝑗   [3] 
 
Where ?̂?1 is an estimate of the ln(odds ratio) of the association between treatment and outcome 
adjusted for confounders 𝑍.  
 
Propensity score analysis 
An alternative to LR models is to first estimate the associations of the confounder with the 
treatment variable. As a second step, the (logit of the) predicted probability of treatment (i.e., the 
propensity score) can be used to control for confounding:  
 
𝑃𝑆 = 𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑜𝑏[𝑥𝑖 = 1| 𝑧𝑖𝑗]) =  ?̂?0 + ?̂?1𝑧𝑖1 + ⋯ + ?̂?𝑗1𝑧𝑖𝑗     [4] 
 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑜𝑏[𝑦𝑖 = 1|𝑥𝑖, 𝑝𝑠𝑖]) =  ?̂?0 + ?̂?1𝑥𝑖 + ?̂?2𝑝𝑠𝑖    [5] 
 
Here ?̂?1, can be interpreted as the ln(odds ratio) of the treatment outcome association adjusted 
for the confounders included in step 1. Because PS models regresses exposure on the 
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confounders, instead of the event, PS models is known to be able to adjust for more 
confounders when the treatment is more common than the outcome. 
 
Disease risk score adjustment 
Another approach to control for confounding is adjustment using a disease risk score (DRS). 
First, the associations between the confounders and outcome are estimated in a training 
dataset, using equation 3. In the second stage, these associations are used to calculate the logit 
of the predicted probability of the outcome (the DRS) for the patients included in the test data. 
Controlling for the DRS variable in a model regressing the outcome on treatment, results in a 
confounding adjusted treatment outcome association: 
 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑜𝑏[𝑦𝑖 = 1|𝑥𝑖, 𝑑𝑟𝑠𝑖]) =  𝛾0 + 𝛾1𝑥𝑖 + 𝛾2𝑑𝑟𝑠𝑖     [6] 
 
𝛾1, can be interpreted as the ln(odds ratio) of the association between treatment and the 
outcome, adjusted for the confounders included in the first stage. 
 
Depending on the size of the training dataset a (very) large number of confounder can be 
including using this DRS method. This makes DRS models particularly interesting for post-
launch settings. However, ideally a training dataset is used in which all patients are untreated 16, 
yet this is often impossible. To explore this, subjects in the simulated training data were 
exposed to drug C or B. Four DRS model were subsequently applied with the first DRS model 
ignoring treatment in the training data (DRS 1). In the DRS 2 model, the treatment variable was 
included in the training model. In the DRS 3 model a treatment by confounder 𝑍1 interaction was 
included. Instead of assuming that all interactions are appropriately modelled, DRS 4 prevented 
interaction by restricting the training dataset to subjects treated with drug C (the reference). 
Note that these four DRS models differed in how treatment was handled in training data, 
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however, analysis of the test data did not differ and entailed including the DRS in a logistic 
regression model regressing outcome on treatment (equation 6). 
 
Simulation scenarios 
In all simulations two datasets were generated, a training and test dataset. For both dataset 
(unless stated otherwise) the association of the continuous confounders 𝑍1 with treatment and 
outcome was set to an odds ratio (OR) of 0.60 per unit increase. The associations of the 
remaining binary confounders with treatment and the outcome were set to an OR of 0.97. The 
association of treatment with the outcome was set to an OR of 1.00. See Table 1 for an 
overview.  
 
In scenario I different EPCs were generated by increasing the number of coefficients from 20 to 
400. EPC was calculated as follows, 𝐸𝑃𝐶 =
200
2+𝑗
  where 𝑗 = {18, 38, 78, 198, 398}, the 200 in the 
numerator representing the expected number of events and the 2 in the denominator 
representing the intercept and treatment coefficient. For the PS model, the EPC was calculated 
by taking the number of subjects expected to be exposed to drug A (200) and dividing this by 𝑗 
confounder coefficients plus the intercept coefficient. In scenarios II and III EPC was set to 10 
in the test data, the treatment and interaction OR in the training data were set to 0.30 and 0.30 
(for scenario II) or 3.00 and 0.30 (for scenario III). To determine in more detail the susceptibility 
of the DRS models for misspecification, the interaction effect in the training data was set to 0.30, 
0.70, 1.00, 1.50 and 3.00 in scenario IV, while the EPC was set to 2.5. In scenario V the 
treatment OR in the training data was set to 0.30, 0.70, 1.00, 1.50 and 3.00 and the interaction 
effect to 3.00. In scenario VI power (i.e., the probability to detect an association if it is present) 
was explored by setting the treatment OR in the test data to 0.30, 0.70, 1.00, 1.50 and 3.00. 
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Finally, scenario VII was created to explore performance is less extreme settings as those 
previously explored.  
 
All simulations were repeated 10 000 times and were performed with the statistical package R 
version 3.0.2 17. The number of replication was chosen to ensure sufficient precision to detect 
small deviations from the typical coverage rate of 0.95 (the 95% lower and upper bounds were 
0.946 and 0.954) 18,19. Furthermore, with 10 000 replications the 95% upper and lower bounds 
around a mean odds ratio of 1.00 was 0.996 and 1.004 (calculated using the empirical SE of the 
unadjusted OR which was constant across scenarios). 
  
Performance metrics 
The different methods to control for confounding were compared on the mean odds ratio, mean 
relative bias (see Appendix), the coverage rate, the mean estimated standard error (SE) (see 
Appendix)15, the empirical SE (see Appendix), the square root of the mean squared error 
(RMSE) 18, power, number of models that failed to converge and the number of models with 
implausible estimates. Mean relative bias was defined as: 𝐸 [
𝑂?̂?−𝑇𝑟𝑢𝑒 𝑂𝑅
𝑇𝑟𝑢𝑒 𝑂𝑅
] ∗ 100, where E 
indicates the expectation, 𝑂?̂? the estimated treatment OR and True OR the simulated treatment 
OR. The coverage was defined as the number of times the true value was included in the Wald 
based 95% confidence interval. The mean SE was defined as the mean of the estimated 
standard errors 15,18. The empirical SE was estimated by taking the standard deviation of the 
distribution of 𝑂?̂?. The RMSE was calculated by taking the square root of the sum of the 
squared bias and the squared empirical SE18. Power equalled the proportion of simulations in 
which the null-hypothesis of 𝑂𝑅 = 1 was correctly rejected, i.e., when the null-hypothesis was 
false (scenario VI). Implausible estimates were defined as treatment |ln (𝑂𝑅)̂ | > 5.  
 
9 
 
Sensitivity analysis. 
Instead of using DRS models when the number of EPC is very small, Firth penalized logistic 
regression (PLR) models have shown promise 20-22 in such settings. To explore this alternative 
to DRS models, scenario I was repeated with LR, PS and a PLR models. PLR was implement 
using the package logistf version 1.21 23. For comparisons sake Wald based p-values were 
calculated, however the reader should note that better performance is expected using profile 
likelihood p-values.  
 
Results 
Table 2 shows the results of the simulations evaluating the LR, PS and DRS models under 
different EPCs (scenario I), in the absence of a treatment effect. Relative bias of the LR and PS 
models was similar up to and including an EPC of 2.5. After this the LR model showed extreme 
bias. Relative bias of the PS model increased to 8.80% at an EPC of 1.0. Mean and empirical 
SE increased for both methods as EPC increased and extreme estimates were seen after EPC 
of 2.5 (for the LR) and 1.0 (for the PS). The coverage rate of LR model started to deviate from 
0.95 at an EPC of 5.0 (0.936), with a more serious deviation at an EPC of 1.0 (0.651). For the 
PS models the coverage rate started to deviated from 0.05 at an EPC of 1.0 (0.939). 
  
In the same scenario I, the mean odds ratios of the different DRS methods already deviated 
more than could be explained by random error at an EPC of 10. However, the bias was only 
small (1.38%) and increased to a maximum of 18.84% at an EPC of 0.5. The relative bias of the 
DRS model 4 was consistently larger than that of the other DRS models. . After an EPC of 5.0 
the coverage rates of the DRS models were smaller than 0.95. Throughout the RMSE increased 
as the ECP increased.  
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In scenario II and III model misspecification of DRS 1 and 2 were introduced by adding a 
treatment by confounder interaction to the training data. In scenario II (interaction OR 0.30) the 
relative bias was small and the coverage rates were close to 0.95 for all methods (Table 3). In 
scenario III (interaction OR 3.00) DRS model 1 and 2 showed relative bias of 9.22% and 
16.94%. Similarly, the coverage rates of these models were 0.930 and 0.881. On the other hand 
DRS models 3 and 4 showed coverage rates close to 0.95 and relative bias of 1.87% and 
3.25%.  
 
In Figure 1 the relative bias, coverage rates and RMSE of the simulation results of scenarios IV 
and V are presented. In scenario IV the treatment by confounder interaction effect was iterated 
from 0.30 to 3.0 at an EPC of 2.5. As expected, the relative bias of the LR and PS was small, 
and the coverage rate of the LR model was consistently 0.92, while the PS estimates had 
correct coverage of 0.95 (Figure 1, column 1). The relative bias of DRS model 1 was more or 
less symmetric and peaked at 14.6% for an interaction effect of 3.0. At an interaction effect of 
0.30 DRS model 2 had the least amount of bias (2.52%). This increased to a bias of 19.27% 
with an interaction effect of 3.00. Relative bias of DRS model 3 and 4 was almost constantly 
about 5% or 8%. A marked increase was only seen for an interaction effect of 0.30.  
 
In scenario V (Figure 1, column 2) the treatment effect in the training data was iterated from 
0.30 to 3.00. All models performed very similar regardless of the treatment effect. The exception 
being DRS model 1 were the relative bias decreased from 14.42% to 8.66% as treatment 
increased to 3.00.  
 
Empirical power was explored in scenario VI (depicted in figure 2), EPC 2.5. Power was below 
0.40 for treatment effects between 0.70 and 1.50; at treatment ORs of 0.30 and 3.00 power was 
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almost 1.00. LR models were consistently more powerful than PS models; however previous 
results showed that in these settings coverage of the LR estimate is less than 0.95.  
 
In scenario VII the DRS models were evaluated with an EPC of 10 with smaller confounder and 
interaction effects. In these settings the relative bias of the DRS models ranged from 0.86% 
(DRS 3) to 1.94% (DRS 2), compared to -0.09% for the LR and -0.10% for the PS and coverage 
rates were close to 0.95 for the DRS and PS methods but not for the LR method (0.941).  
 
In all scenarios every model converged and no estimates were excluded. However, in scenario I 
extreme values were observed for the LS and PS models. Arbitrarily defining extreme, as an 
estimate above 5, resulted in excluding 7,243 and 9,421 of the 10,000 estimates for the LR 
method at an EPC of 1.0 and 0.05. For the PS model this resulted in excluding 4,711 estimates 
at an EPC of 0.05.  
 
Results of the sensitivity analyses comparing PS and LR models to the PLR methods are 
presented in Appendix Table 1. Briefly, the PLR model showed a maximum relative bias of -
9.13% and coverage rate of 1.000 at an EPC of 0.5. At an EPC of 1.0 relative bias and 
coverage rate of the PLR model was -0.16% and 0.931, at 0.5 this was -9.13% and 1.000. With 
regard to coverage the PS model performed similar to the PLR model, however bias was larger 
(8.75%, 0.942 at an EPC 1.0 and -98.56% and 0.973 at an EPC of 0.05).  
 
Discussion 
Our simulations show that, in settings with a relatively small number of events/exposed per 
coefficient (EPC), disease risk score (DRS) and propensity score (PS) methods provided less 
biased estimates of the association between treatment and outcome than logistic regression 
(LR). While DRS methods were more biased than LR and PS methods when EPC was large 
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(i.e., 10), in smaller settings they outperformed both. However, this was at the cost of a smaller 
coverage rate than the PS method. Additionally, DRS models were sensitive to misspecification 
of the treatment by confounder interaction effect. With DRS models, excluding the interaction 
effect, showing bias of 17% versus 2% to 3% when the interaction was appropriately modelled. 
However, in settings with less confounding and model misspecification bias was at most 1.94%. 
Finally, we showed that the PS method needs less exposed subjects per coefficient than LR 
method needs events per coefficient.  
 
In our simulations the PS estimates were the least biased while keeping a coverage rate closest 
to the nominal 0.95. Additionally, in a sensitivity analysis PS models had similar coverage rates 
as penalized logistic regression models; a method which is generally expected to perform best 
in small EPC settings. Previously, Cepeda et.al.,24 also explored EPC of PS models, focussing 
on the number of outcome events. Recognizing that PS model performance is more influence 
by the number of exposed than the number of event, the present simulations focussed on the 
number of exposed subjects per coefficient. For comparisons sake the proportion exposed and 
events was set to 0.50. We recognize that in most empirical studies, the proportion of exposed 
subjects will be closer to 0.50 than will be the proportion of events. Thus in most empirical 
studies the benefit of using PS models over LR and DRS models is expected to be greater than 
shown here. However, in small EPC settings where proportion of exposed subjects is less than 
the proportion of events, DRS method will likely outperform both LR and PS methods. In setting 
where EPC was 1.0 or less, DRS estimates were less biased and coverage was closer to 0.95 
than estimates from PS and LR methods, however, coverage still deviated from 0.95. 
Essentially, in these settings, all methods failed and perhaps inclusion of additional subjects 
would be a more reasonable solution. Furthermore, at the tipping point of an EPC of 2.5, power 
was less than 40%, unless large treatment effects were present (OR > 1.5). Unless such a large 
effect is to be expected, inclusion of more subjects might again be the best solution. Finally, we 
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note that in all simulations the PS model consistently included one coefficient less than the LR 
model. This resulted in a slightly larger EPC: 10.53, 5.13, 2.53, 1.01, 0.50. This small difference 
seems unlikely to explain the improved performance of the PS models.  
 
Previous simulation studies on DRS models trained the DRS in the tests data 13,15. Because the 
same number of events is available, these DRS models cannot include more confounder than 
regular LR models and where not considered here. Instead we focussed on DRS models with 
an independent and larger training dataset. Depending on the size of the training data, these 
DRS models can potentially adjust for an enormous number of confounders. We expected bias 
to remain stable over increasing EPCs (due to the size of the training data). However, in our 
simulations bias did increase, which was probably due to an increase in random difference 
between the associations in the training and test data (due to an increase in variables as EPC 
increased). Obviously, this bias could be decreased by increasing the size of the test data. 
However when the test data increases in size the need for DRS model is less apparent and LR 
models might be a better choice. Surprisingly, DRS model 4, which limited the derivation 
dataset to subjects treated with drug C only, consistently showed larger bias than the other DRS 
models. As Wyss et.al discusses this bias is caused by overfitting the model to the reference 
group 25.  
 
The simulations presented here are naturally limited. We feel that the following points merit 
discussion. First, in our simulations we predominantly focused on dichotomous confounders. 
Because continuous data is less sensitive to small cell counts it seems likely that if the 
simulations were repeated with only continuous confounders, bias would be smaller. Second, 
previous studies that explored EPC fixed both the number of event and the number of 
covariables. In the current paper we only fixed the number of covariables, and the number of 
events was an average. We feel that this approach more closely follows research practice, 
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where at the design phase it is possible to specify which and how many confounder would be 
included, however, only an expected number of event can be specified 26. Thirdly, while we 
focussed on the situation where confounders are pre-specified 27, our results are also relevant 
for researchers wishing to reduce model complexity using e.g., backward selection methods. In 
the first stage of such an approach a full model is constructed which is equal to the pre-specified 
model applied here and similar concerns on model misspecification and EPC apply. Note, 
however, that applying model selection in LR models will increase the type 1 error rate, of the 
treatment association, beyond the level shown here 28,29. Finally, all PS and DRS models were 
implemented using generalized linear models (GLMs). In empirical data, typically, the functional 
form of the PS or DRS with the outcome is unknown; hence, it seems advisable to use 
nonparametric methods such as matching or stratification. In our simulations however, the 
functional form was known and no disadvantage of using GLMs is expected  
 
In conclusion, when the number of events and the number of exposed subjects are equally 
sparse disease risk models result in the least biased point estimates, however, at the cost of a 
smaller coverage rate. The propensity score estimates are more biased at an ECP of 1.0 and 
0.5, however, coverage levels are close to 0.95. Depending on the settings and aim of the 
research, estimation or testing, a different method might be preferred. However, at very low 
EPCs (0.5) all methods had bias and coverage levels below acceptable levels and a better 
approach would be to include more subjects.  
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Tables 
Table 1 Simulation scenarios, assessing performance of different confounding adjustment methods*. 
Parameters Scenario I Scenario II Scenario III Scenario IV Scenario V Scenario VI Scenario VII 
        
Training data        
Sample size [𝑛] 5000 5000 5000 5000 5000 5000 5000 
OR of reference treatment A vs. 
treatment B [𝛿1] 
1.00 0.30 0.30 0.30 {0.3, 0.70, 
1.00, 1.50, 
3.0} 
0.30 0.90 
OR of treatment by Z1 interaction 
[𝛿𝑖𝑛𝑡] 
1.00 0.30 3.0 {0.3, 0.70, 
1.00, 1.50, 
3.0} 
3.00 3.00 1.25 
Confounder Z1 OR (event 
[𝛿2]/treatment[𝛼1]) 
 
0.60/0.60 0.60/0.60 0.60/0.60 0.60/0.60 0.60/0.60 0.60/0.60 0.80/0.80 
Other confounders (event 
[𝛿𝑗−1]/treatment[𝛼𝑗−1]) 
0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 
        
Test data        
Sample size [𝑛] 400 400 400 400 400 400 400 
OR of reference treatment A vs. 
treatment C [𝛿1] 
1.00 1.00 1.00 1.00 1.00 {0.3, 0.70, 
1.00, 1.50, 
3.0} 
1.00 
OR of treatment by Z1 interaction 
[𝛿𝑖𝑛𝑡] 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Events per coefficient  {10, 5, 2.5, 
1, 0.5} 
10 10 2.5 2.5 2.5 10 
Number of coefficients 20-400 20 20 80 80 80 20 
Confounder Z1 OR (event 
[𝛿2]/treatment[𝛼1]) 
0.60/0.60 0.60/0.60 0.60/0.60 0.60/0.60 0.60/0.60 0.60/0.60 0.80/0.80 
Other confounders (event 
[𝛿𝑗−1]/treatment[𝛼𝑗−1]) 
0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 0.97/0.97 
* Changes from the previous scenario (on the left) are presented in bold. 
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Table 2 Simulation results from scenario I assessing performance of different confounding adjustment methods with 
different events per coefficient*. 
 10 EPC 5 EPC 2.5 EPC 1 EPC 0.5 EPC 
Mean odds ratio      
LR 1.00 1.00 1.00 N/A# 9.2*10118 
PS 1.00 1.00 1.00 1.09 1.2*109 
DRS1 1.01 1.03 1.05 1.10 1.15 
DRS2 1.01 1.03 1.05 1.10 1.15 
DRS3 1.01 1.03 1.05 1.10 1.15 
DRS4 1.03 1.05 1.08 1.13 1.19 
Relative bias      
LR 0.05 -0.06 -0.49 N/A# 9.2*10120  
PS 0.00 -0.12 -0.30 8.80 1.2*1011 
DRS1 1.38 2.57 4.57 9.53 14.70 
DRS2 1.38 2.57 4.57 9.53 14.71 
DRS3 1.39 2.59 4.61 9.56 14.72 
DRS4 2.55 4.62 7.52 13.40 18.84 
Coverage      
LR 0.946 0.936 0.920 0.651 1.000 
PS 0.954 0.950 0.954 0.939 0.975 
DRS1 0.951 0.949 0.945 0.926 0.898 
DRS2 0.951 0.949 0.945 0.926 0.898 
DRS3 0.950 0.949 0.945 0.927 0.898 
DRS4 0.948 0.945 0.936 0.904 0.867 
SMSE      
LR 0.22 0.25 0.30 2.9*1014 1.7*104 
PS 0.21 0.22 0.23 0.27 1317.99 
DRS1 0.21 0.21 0.21 0.23 0.25 
DRS2 0.21 0.21 0.21 0.23 0.25 
DRS3 0.21 0.21 0.21 0.23 0.25 
DRS4 0.21 0.21 0.22 0.24 0.25 
* SMSE = square root of the mean squared error.  # While all LR samples converged,  
the OR estimate was exp(5.42*1012) resulting in an error when calculating the mean OR and relative bias. 
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Table 3 Simulation results from scenario II and III comparing different DRS models  
in the presence of an interaction effect in the training data*. 
 LR PS DRS1 DRS2 DRS3 DRS4 
Scenario II# 
Mean odds ratio  
Relative bias 
Coverage 
RMSE 
 
 
1.00 
-0.16 
0.950 
0.22 
 
1.00 
-0.19 
0.956 
0.21 
 
1.05 
5.10 
0.947 
0.21 
 
1.01 
0.51 
0.954 
0.21 
 
1.02 
2.19 
0.954 
0.21 
 
1.04 
4.14 
0.949 
0.21 
Scenario III^ 
Mean odds ratio  
Relative bias 
Coverage 
RMSE 
 
1.00 
0.27 
0.948 
0.22 
 
1.00 
0.23 
0.954 
0.21 
 
1.09 
9.22 
0.930 
0.22 
 
1.17 
16.94 
0.881 
0.26 
 
1.02 
1.87 
0.952 
0.21 
 
1.03 
3.25 
0.950 
0.21 
* SMSE = square root of the mean squared error.  # Treatment by confounder 1 interaction OR of 0.30. 
 ^ Treatment by confounder 1 interaction OR of 3.0 
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Figure captions 
Figure 1 Simulation results from scenarios IV and V comparing different DRS models to PS and 
LR models on relative bias, coverage rate and square root of the mean squared error (RMSE). * 
 
[Figure 1 here] 
 
* line number 1 logistic regression; line number 2 propensity score; line number 3 disease risk score 
(DRS) 1 model; line number 4 DRS 2; line number 5 DRS 3 and line number 6 DRS 4.  
 
Figure 2 Simulation results from scenario VI comparing different DRS models to PS and LR 
models on power.* 
 
[Figure 2 here] 
 
* line number 1 logistic regression; line number 2 propensity score; line number 3 disease risk score 
(DRS) 1 model; line number 4 DRS 2; line number 5 DRS 3 and line number 6 DRS 4.  
 
 
 
